Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
Phase 1
- Conditions
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 54
- Registration Number
- NCT00538005
- Locations
- 🇺🇸
San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
Phase 2
- Conditions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 80
- Registration Number
- NCT00492687
- Locations
- 🇺🇸
San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
Phase 2
- Conditions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT00492505
- Locations
- 🇺🇸
San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Phase 2
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 50
- Registration Number
- NCT00489944
- Locations
- 🇺🇸
San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States
© Copyright 2024. All Rights Reserved by MedPath